Stroke prevention in patients with atrial fibrillation (AF) is one pillar of the management of
this common arrhythmia. Substantial advances in the epidemiology and associated …

Background In patients with atrial fibrillation (AF) and normal or slightly impaired renal
function, the use of direct oral anticoagulants (DOACs) is preferable to vitamin K antagonists …

Background Atrial fibrillation (AF) Better Care (ABC) pathway adherence is associated with
improved outcomes. Clinical trials have shown that non-vitamin K antagonist oral …

Atrial fibrillation is a condition which frequently occurs in the elderly causing a contraction of
a portion of the heart. It can be either perceived as an uncomfortable sensation or it may be …

OBJECTIVE: Non-valvular atrial fibrillation (NVAF) is a common manifestation of cardiac
arrhythmia, whose significance is heightened in the context of an aging global population …

Introduction For a long time, vitamin K antagonists (VKA) were the only oral anticoagulation
therapy available to reduce adverse events in atrial fibrillation (AF) patients. Direct-acting …

Over the past two decades, percutaneous left atrial appendage occlusion (LAAO) has
proven to be a viable alternative to oral anticoagulation (OAC) for stroke prevention in …

Background The sequelae of myocardial infarction (MI) require specific pharmacological
therapy to minimise the post-MI remodelling, which in many cases evolves into …

Background The introduction of non-vitamin K antagonist oral anticoagulants (NOACs), with
a non-inferior or superior clinical efficacy profile compared to vitamin K antagonists (VKAs) …

Background To assess long-term effectiveness and safety of edoxaban in Europe. Methods
and results ETNA-AF-Europe, a prospective, multinational, multi-centre, post-authorisation …